Whitehawk Therapeutics, Inc.

Public biopharma companies usually spend the week before the J.P. Morgan Healthcare Conference announcing new financings, partnerships and sometimes data so that they have compelling milestones to dis

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Kaken Obtains Aadi’s Fyarro, Comm

BioMarin Pharmaceutical Inc. followed up its recent announcement of a shift in research and development priorities and a new commercial strategy for its hemophilia A gene therapy Roctavian (valoctoco

AADi Bioscience, Inc. ’s Fyarro (nab-sirolimus) is the first drug approved by the US Food and Drug Administration for locally advanced unresectable or metastatic malignant perivascular epithelioid cel